-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Market data
| Diprivan | Emla | Imuran | Ovestin | Ultiva | Xylocaine topicals |
|---|---|---|---|---|---|
| General anaesthetic | Topical anaesthetic | Immunosuppressant | Estrogen hormone replacement | Opioid analgesic | Topical anaesthetic |
0
Products
Launched
Launched
(2024: 17)
0
Product
Recalls
Recalls
(2024: 1)
0
%
Average Staff
Turnover
Turnover
(2024: 11%)
0
Work-related
Fatalities
Fatalities
(2024: Nil)
90
Sales
Representatives
Representatives
(2024: 118)
400
Permanent
Employees
Employees
June 2025
400
Permanent
Employees
Employees
(June 2024)
Products
Launched
Launched
(2022: Nil)
0
Product
Recalls
Recalls
(2022: 5)
0
%
Average Staff
Turnover
Turnover
(2022: 9%)
Work-related
Facilities
Facilities
(2022: Nil)
50
Sales
Representatives
Representatives
(2022: 140)
900
Permanent
Employees
Employees
(June 2022: 2,192)
| Revenue | 2025 R'million |
2024 (CER) R'million |
Change % |
|---|---|---|---|
| Commercial Pharmaceuticals | 4 706 | 4 779 | (2) |
| Over the counter | 1 973 | 1 939 | 2 |
| Injectables | 1 690 | 1 868 | (10) |
| Prescription | 1 043 | 972 | 7 |
| Manufacturing | 9 976 | 12 433 | (20) |
| Active pharmaceutical ingredients | 4 487 | 4 716 | (5) |
| Finished dose form | 4 159 | 4 033 | 3 |
| Heparin | 1 330 | 3 684 | (64) |
| Total | 14 682 | 17 212 | (15) |
Note: Commercial Pharmaceuticals' revenue is by customer geography and Manufacturing revenue is by place of manufacture.
CER: Constant Exchange Rate
CER: Constant Exchange Rate
Contribution to Group revenue (%)
2025
Rest of Group
66
Europe CIS
34
Revenue by segment (%)
2025
Active pharmaceutical ingredients
31
Finished dose form
28
Over the counter
13
Injectables
12
Heparin
9
Prescription
7
- Europe Middle East region market value as of Q2 2025 is EUR 337 billion, growing at a compound annual growth rate of 5,7%*.
- Top markets by sales contribution include Germany (18,0%), France (13,7%), Italy (13,0%), UK (12,1%) from EU and Saudi Arabia (4,0%), Turkey (3,2%), Egypt (1,5%) from Middle East*.
- Europe Middle East region is expected to grow further, reaching sales of EUR398,5 billion by 2028, driven by the introduction of innovative and high-priced medicines, an ageing population, lifestyle diseases, and increased insurance coverage*.
Source: IQVIA Midas MAT, Q2-2025. IQVIA global use of medicine, 2025 through 2029.
